Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page now shows Revision: v3.4.2; the prior government-funding lapse notice and the Revision: v3.4.1 entry were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedNotice: Added a government funding lapse banner and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated footer labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with the site revision updated to v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedThe page metadata was updated: 'Type 2 diabetes' added with related topic 'MedlinePlus Genetics', and the page revision updated from v3.3.3 to v3.3.4.SummaryDifference0.2%

- Check56 days agoChange DetectedType 2 diabetes and the related topics MedlinePlus Genetics were removed from the page's topics/MeSH section.SummaryDifference0.2%

- Check63 days agoChange DetectedFooter updates include adding Revision: v3.3.3 and removing HHS Vulnerability Disclosure and Revision: v3.3.2; core study content and details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.